Background and aims: microRNA-605 (miR-605) is dysregulated in multiple cancers and plays crucial roles in regulating cancer progression. However, little is known about the expression pattern and detailed roles of miR-605 in non-small-cell lung cancer (NSCLC). Thus, in this study, we evaluated miR-605 expression in NSCLC along with its clinical significance. More importantly, the detailed roles and the underlying molecular mechanisms of miR-605 in NSCLC were explored. Material and methods: Quantitative reverse transcription polymerase chain reaction (RTqPCR) was employed to detect miR-605 expression in NSCLC tissues and cell lines. A series of experiments were performed to determine the effects of miR-605 upregulation on NSCLC cell proliferation, apoptosis, migration and invasion in vitro and tumor growth in vivo. In addition, the downstream regulatory mechanisms of miR-605 action in NSCLC cells were explored. Results: Decreased expression of miR-605 was frequently detected in NSCLC tissues and cell lines. Low expression of miR-605 was significantly correlated with the tumor size, TNM stage, and distane metastasis in NSCLC patients. Exogenous miR-605 expression inhibited proliferation, increased apoptosis, and inhibited metastasis of NSCLC cells in vitro. Additionally, miR-605 overexpression hindered the growth of NSCLC cells in vivo. Furthermore, Forkhead Box P1 (FOXP1) was identified as a direct target gene of miR-605 in NSCLC cells. Moreover, FOXP1 was highly expressed in NSCLC cells and showed an inverse correlation with miR-605 expression levels. Besides, silencing of FOXP1 simulated roles similar to miR-605 upregulation in NSCLC cells. FOXP1 reintroduction partially abolished the anticancer effects of miR-605 in NSCLC cells. Conclusion: Our results revealed that miR-605 inhibited the oncogenicity of NSCLC cells in vitro and in vivo by directly targeting FOXP1, suggesting the importance of the miR-605/ FOXP1 pathway in the malignant development of NSCLC.
Introduction
Lung cancer is one of the most frequently diagnosed human malignancies and the leading cause of cancer-related deaths globally.
1 Approximately 1.825 million newly diagnosed cases and 1.59 million mortalities caused by lung cancer are predicted every year all over the world. 2 Lung cancer could be divided into two main subtypes, non-small-cell lung cancer (NSCLC) and small-cell lung cancer, which account for 85% and 15% of all lung cancer cases, respectively. 3 Currently, the primary therapy for NSCLC is surgical resection, followed by chemotherapy, radiotherapy, and other anti-tumor therapy. 4 With the notable development of therapeutic strategies in recent years, the treatment outcomes of patients with all stages of NSCLC have improved to a certain extent; however, the curative effects of cancer therapy remain unsatisfactory. 5 Therefore, an in-depth elucidation of the mechanisms underlying the occurrence and development of NSCLC is imperative to the development of novel and effective therapeutic targets for patients with this fatal disease. microRNAs (miRNAs) are a group of non-coding, short RNA molecules made up of 17-24 nucleotides. 6 miRNAs function as endogenous RNA silencing molecules through complementary binding to the 3′-untranslated regions (3′-UTRs) of their target genes, resulting in mRNA degradation or promoting gene silencing by suppressing translation. 7 Emerging studies have demonstrated that the expression of miRNA molecules is abnormal in most human malignancies and they play crucial roles in tumorigenesis and tumor development. [8] [9] [10] A variety of miRNAs have been reported to be aberrantly expressed in NSCLC. 11 For example, miR-212, 12 miR-409, 13 and miR-4317 14 are downregulated in NSCLC, whereas miR-21, 15 miR-105, 16 and miR-421 17 are expressed at high levels. Dysregulation of miRNA is closely related with the progression and development of NSCLC through participating in the regulation of multiple biological behaviors, thus acting either as oncogenes or tumor suppressors. 18 Hence, identifying new miRNAs and investigating their roles in NSCLC progression might facilitate the identification of novel therapeutic targets for treating patients with NSCLC in the future. miR-605 is dysregulated in multiple cancers and play crucial roles in regulating cancer progression. [19] [20] [21] However, little is known about the expression pattern and detailed roles of miR-605 in NSCLC. Thus, in this study, we detected the expression of miR-605 in NSCLC and investigated its clinical significance. More importantly, the detailed roles and the underlying molecular mechanisms of miR-605 in NSCLC were elucidated.
Materials and methods

Tissue specimens
Paired NSCLC tissues and adjacent normal lung tissues were collected from 45 patients who underwent surgical resection at Liyuan Hospital of Tongji Medical College of Huazhong University of Science and Technology between October 2015 and November 2017. None of the patients had received chemotherapy, radiotherapy or other anti-tumor therapy before surgical resection. Tissue specimens were resected, frozen in liquid nitrogen, and then stored at −80°C until RNA extraction. This research was approved by the Ethics Committee of Liyuan Hospital of Tongji Medical College of Huazhong University of Science and Technology, and was performed in accordance with the Declaration of Helsinki. In addition, written informed consent was obtained from all participants prior to their enrolment in this study.
Cell lines and culture conditions
A non-tumorigenic bronchial epithelium cell line BEAS-2B and four human NSCLC cell lines (H460, SK-MES-1, H522, and H1299) were purchased from Shanghai Institute of Biochemistry and Cell Biology (Shanghai, China). The cells were routinely cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS) (both from Gibco, Thermo Fisher Scientific, Inc., Waltham, MA, USA) and 1% v/v penicillinstreptomycin (Sigma-Aldrich, St. Louis, MO, USA). All cells were cultivated in a humidified incubator at 37°C supplied with 5% CO 2 .
Cell transfection experiments miR-605 mimics and negative control miRNA mimics (miR-NC) were ordered from Guangzhou RiboBio Co., Ltd (Guangzhou, China). Small interfering RNA (siRNA) targeting FOXP1 expression (si-FOXP1) and negative control siRNA (si-NC) were chemically synthesized by GenePharma Co. Ltd. (Shanghai, China). FOXP1 overexpression vector pCMV-FOXP1 and pCMV empty plasmid was generated by GeneCopoeia Co. Ltd. (Guangzhou, China). For transfection, cells were plated into 6-well plates with a density of 5×10 5 or miR-NC were subcutaneously injected into the rear flank of nude mice. The tumor width and length were measured every four days and the tumor volume was analyzed using the formula V (mm3) = width2 (mm2) × length (mm)/2. One month later, all nude mice were executed, and the xenografts were dissected out and weighed.
Target prediction and luciferase reporter assay
The putative targets of miR-605 were predicted using three miRNA target prediction software, including miRDB (http://www.mirdb.org/), miRanda (http://www.microrna. org), and TargetScan (http://www.targetscan.org/).
The 3ʹ-UTR fragments of FOXP1 containing the wildtype miR-605 binding sequences and mutant FOXP1 3ʹ-UTR were amplified by GenePharma Co. Ltd., and cloned into the pMIR-REPORT vector (Promega, Madison, WI, USA). These reporter plasmids were designated as wildtype pMIR-FOXP1-3ʹ-UTR and mutant pMIR-FOXP1-3ʹ-UTR, respectively. Cells were inoculated into 24-well plates one day prior to transfection. miR-605 mimics or miR-NC, in combination with wild-type pMIR-FOXP1-3ʹ-UTR or mutant pMIR-FOXP1-3ʹ-UTR, was introduced into cells using Lipofectamine™ 2000, in accordance with the manufacturer's instructions. At 48 h after treatment, transfected cells were harvested and luciferase activity was detected using a Dual-Luciferase Reporter Assay system (Promega, Madison, WI, USA). Firefly luciferase activity was normalized against Renilla luciferase activity.
Western blot analysis
Cells or homogenized tissues were lysed using radioimmunoprecipitation assay lysis buffer (Beyotime Institute of Biotechnology, Shanghai, China) containing a protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA). The concentration of total protein was quantified using a BCA Protein Assay Reagent kit (Pierce, Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer's protocol. Equal amounts of total protein were separated using a 10% SDS-PAGE gel and then transferred onto PVDF membranes (EMD Millipore, Billerica, MA, USA).
Subsequent to blocking at room temperature with 5% fat-free dried milk diluted in Tris-buffered saline with 0.1% Tween-20 (TBST) for 2 h, the membranes were incubated with the primary antibodies overnight at 4°C. The primary antibodies used in this study were as follows: rabbit anti-human FOXP1 antibody (1:1,000, cat. no. ab196978) and rabbit anti-human GAPDH antibody (1:1,000, cat. no. ab181603, both from Abcam, Cambridge, UK). Horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (cat. no. ab205718, Abcam, Cambridge, UK) was used at a dilution of 1:5,000 for 2 h at room temperature and the protein signals were detected using a Pierce ECL Western Blotting Substrate (Pierce, Thermo Fisher Scientific, Inc., Waltham, MA, USA).
Statistical analysis
All results from at least three independent experiments were shown as mean ± standard deviation and analyzed using SPSS software, v. 19.0 for Windows (IBM Corp.
Armonk, NY, USA). Student's Two-tailed t-test was used for comparison of two treatment groups. One-way analysis of variance followed by the Bonferroni post hoc test was performed to evaluate the differences between multiple groups. Chi-square test was employed to determine the correlation of expression of miR-605 and clinicopathological characteristics in NSCLC patients. The association between FOXP1 mRNA and miR-605 expression levels was analyzed by Spearman's correlation analysis. P<0.05 was considered to indicate a statistically significant difference.
Results
miR-605 expression is decreased in NSCLC tissues and cell lines
To examine the expression status of miR-605 in NSCLC, RT-qPCR was performed to detect miR-605 expression in 45 pairs of NSCLC tissues and adjacent normal lung tissues. The results showed that the expression level of miR-605 was notably lower in NSCLC tissues than that in adjacent normal lung tissues ( Figure 1A , P<0.05). We next explored the relationship between miR-605 expression and clinico-pathological characteristics, to clarify the clinical value of miR-605 in NSCLC patients. Chi-square test indicated that decreased expression of miR-605 was significantly correlated with tumor size (P=0.026), TNM stage (P=0.004), and distant metastasis (P=0.023), but not with the gender, age, histological tumor type and tumor differentiation (all P>0.05; Table 1 ). Furthermore, the data obtained from RT-qPCR analysis revealed that miR-605 was frequently downregulated in all four NSCLC cell lines (H460, SK-MES-1, H522, and H1299) relative to its expression in a non-tumorigenic bronchial epithelium cell line BEAS-2B ( Figure 1B, P<0.05) . Collectively, these observations strongly implied that a change in miR-605 expression might be related to the progression of NSCLC.
miR-605 inhibits the malignant phenotype of NSCLC in vitro H460 and H522 cell lines showed relatively lower miR-605 expression among the four NSCLC cell lines and hence, these two NSCLC cell lines were selected for further functional assays. To illustrate the role of miR-605 in the aggressiveness of NSCLC cells, H460 and H522 cells were transfected with miR-605 mimics in 
FOXP1 is a direct target gene of miR-605 in NSCLC cells
To elucidate the downstream regulatory mechanism of action of miR-605 in NSCLC cells, bioinformatics analysis was performed to search for the putative target of miR-605. Based on the results, FOXP1 ( Figure 3A ) ignited our interest since this gene plays crucial roles in the progression and development of NSCLC. 23 Luciferase reporter assay was performed to determine whether miR-605 was able to directly target the 3′-UTR of FOXP1 in NSCLC cells. Restoring the expression of miR-605 significantly decreased the luciferase activity of wild-type pMIR-FOXP1-3ʹ-UTR in both H460 and H522 cells (P<0.05), whereas the inhibitory effect was abrogated when the binding sequences of miR-605 in the 3ʹ-UTR of FOXP1 were mutated ( Figure 3B ). To further confirm whether FOXP1 is a direct target of miR-605, we detected its Figure 3C , P<0.05) and protein ( Figure 3D , P<0.05) levels were notably elevated in NSCLC tissues compared to that in adjacent normal lung tissues. Furthermore, an inverse association between miR-605 and FOXP1 mRNA levels was identified in NSCLC tissues ( Figure 3E ; r= −0.5480, P<0.0001). Moreover, decreased FOXP1 mRNA ( Figure 3F , P<0.05) and protein ( Figure 3G , P<0.05) levels were observed in miR-605-overexpressing H460 and H522 cells. Therefore, we drew a conclusion that FOXP1 is the direct target gene of miR-605 in NSCLC cells. of miR-605 in the xenografts. The data showed that the expression level of miR-605 was higher in the xenografts derived from the miR-605-expressing H460 cells ( Figure  6D , P<0.05). Moreover, there was a significant decrease in FOXP1 protein expression in the miR-605 mimics group compared to that in the miR-NC group ( Figure 6E ). These observations demonstrated that miR-605 inhibits the growth of NSCLC cells, in vivo.
Discussion
Recently, the changes in miRNA expression are currently a hot research area. 24, 25 The dysregulation of miRNAs in NSCLC has been widely reported in accumulating studies. [26] [27] [28] Aberrantly expressed miRNAs are closely correlated with the malignant progression of NSCLC and participate in the regulation of various biological behaviors. 11 Hence, in-depth studies of the effects of crucial miRNAs in NSCLC progression might provide a novel insight into their use as potential therapeutic targets for treating patients with this deadly disease. This study, for the first time, detected miR-605 expression in NSCLC, investigated the regulatory roles of this miRNA with respect to the aggressive behaviors of NSCLC and explored the possible underlying mechanisms. miR-605 has been well-studied in multiple types of malignant tumors. For example, miR-605 is downregulated in melanoma tissues and cell lines. Restoring miR-605 expression decreased melanoma cell growth in vitro and in vivo. 19 Expression level of miR-605 was also lower in prostate cancer tissues and cell lines. The upregulation of miR-605 inhibited the proliferation and invasion of prostate cancer cells. 20 A study by Li et al revealed that 29 and it was considered as a glutamine rich factor. FOXP1 is a member of the forkhead box transcription factor family. 30 It is a transcription inhibitor and has been reported to be dysregulated in multiple human cancers. [31] [32] [33] One previous study reported that FOXP1 was upregulated in NSCLC at both mRNA and protein levels. 23 High FOXP1 expression was significantly correlated with gender and histologic type in NSCLC patients. These patients with high FOXP1 expression had shorter five-year survival rate than patients with low FOXP1 expression. 23 Furthermore, Kaplan-Meier survival and cox regression analyses identified FOXP1 expression as an independent biomarker to predict the poor prognosis of patients with NSCLC. 23 In this study, we revealed that inhibition of FOXP1 suppressed NSCLC cell proliferation, promoted cell apoptosis, and decreased cell migration and invasion, in vitro. Notably, miR-605 directly targeted FOXP1, thereby inhibiting the malignant progression of NSCLC cells. Accordingly, targeting FOXP1 by restoring the expression of miR-605 might be an effective therapeutic approach for NSCLC patients.
Conclusion
To our knowledge, this is the first study to confirm that the downregulation of miR-605 is a common phenomenon in NSCLC tissues and cell lines and that this downregulation of miR-605 is significantly correlated with the tumor size, TNM stage, and distant metastasis. In addition, increased miR-605 expression can prohibit the progression of NSCLC in vitro and in vivo by directly targeting FOXP1. These findings might provide a new insight into NSCLC carcinogenesis and miR-605 could be developed as a potential therapeutic target for this cancer type.
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